X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisiton, Vertex expand its immunology portfolio by including Alpine’s ALPN-303 (povetacicept), is a highly potent and effective dual antagonist of BAFF and APRIL. Currently it is on track to enter late stage trial in second half of 2024 for the treatment of IgA nephropathy.
Lead Product(s): Povetacicept
Therapeutic Area: Nephrology Product Name: ALPN-303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Vertex Pharmaceuticals
Deal Size: $4,900.0 million Upfront Cash: $4,900.0 million
Deal Type: Acquisition April 10, 2024
Details:
ALPN-303 (povetacicept) is a BAFF/APRIL inhibitor, subcutaneously administered protein drug candidate, which is currently being evaluated for the treatment of IgA nephropathy.
Lead Product(s): Povetacicept
Therapeutic Area: Nephrology Product Name: ALPN-303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
Under the agreement, Alpine will stop enrollment in the phase 2 study of ALPN-101 (acazicolcept) in systemic lupus erythematosus and AbbVie retains an exclusive option to obtain an exclusive worldwide license to acazicolcept.
Lead Product(s): Acazicolcept
Therapeutic Area: Immunology Product Name: ALPN-101
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $115.0 million Upfront Cash: $60.0 million
Deal Type: Licensing Agreement December 21, 2023
Details:
The net proceeds will be used to further advance the development of ALPN-303 (povetacicept) for multiple autoimmune diseases, including a potential pivotal phase 3 study in IgAN and a phase 2 study in systemic lupus erythematosus.
Lead Product(s): Povetacicept
Therapeutic Area: Nephrology Product Name: ALPN-303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 06, 2023
Details:
The net proceeds will be used to further advance the development of ALPN-303 (povetacicept) for multiple autoimmune diseases, including a potential pivotal phase 3 study in IgAN and a phase 2 study in systemic lupus erythematosus.
Lead Product(s): Povetacicept
Therapeutic Area: Nephrology Product Name: ALPN-303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering November 06, 2023
Details:
ALPN-303 (povetacicept) is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in pathogenesis of multiple autoimmune diseases like IgA Nephropathy.
Lead Product(s): Povetacicept
Therapeutic Area: Nephrology Product Name: ALPN-303
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
ALPN-303 is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in the activation and survival of B cells.
Lead Product(s): ALPN-303
Therapeutic Area: Nephrology Product Name: ALPN-303
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
ALPN-303 is a dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, which play key roles in the activation and survival of B cells.
Lead Product(s): ALPN-303
Therapeutic Area: Immunology Product Name: ALPN-303
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2022
Details:
Decision to terminate enrollment in davoceticept (ALPN-202) conditional CD28 costimulator and dual checkpoint inhibitor studies was made in interest of patient safety after the Company was notified of a second death in the NEON-2 study, attributed to cardiogenic shock.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
The company will use the proceeds from the offering for the development of clinical pipeline including ALPN-303 and for other general and corporate purpose.
Lead Product(s): ALPN-303
Therapeutic Area: Immunology Product Name: ALPN-303
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Morgan Stanley
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering September 20, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
